In this report, we present our experience using this treatment protocol in a larger group of patients who had ventricular tachycardia or ventricular fibrillation refractory to at least two other antiarrhythmic agents . This report corroborates our earlier fading-, (6) as well as reports by others (8) (9) (10) (11) of the efficacy of intravenous amiodarone in smaller groups of patients with drug-refractory ventricular tachycardia and ventricular fibrillation . It extends our previous findings in describing not only the incidence of response, but also the time course of response, the clinical characteristics that predict a successful response, the hospital course of responders and nonresponders, major side effects and long-term follow-up of patients treated with intravenous amiodarone .
Methods
Inclusion and exclusion criteria . Inclusion criteria: Patients with life-threatening recurrent sustained ventricular tachycardia or ventricular fibrillation that did net rev-,00 to at least two other antiarrhythmic medications . Patients were admitted to the study regardless of the severity of cardiac dysfunction .
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Exclusion criteria : I) Patients who had received oral amiodarone for >2 days before initiation of the intravenous drug (four patients) ; 2) patients who had had a myocardial infarction <2 days before initiation of intravenous amiodarone (one patient) ; 3) patients who had taken an antiarrhythmic drug that appeared to have exerted a proarrhythmic effect (onset of new or incessant ventriculartachycardta) and that was stopped at the start of the amiodarone infusion (five patients) .
Of 56 consecutive patients eligible for inclusion, 10 were excluded for the reasons indicated . The remaining 46 patients are the subject of this report . Patients previously reported from this institution by Morady et al. (6) and Schwartz et al . (7) are not included in this report .
Definitions. Sustained ventricular tachycardia : ventricular tachycardia lasting >30 s or requiring intervention for termination.
Incessant ventricular tachycardia : continuous or recurrent episodes of sustained ventricular tachycardia or ventricular fibrillation more frequent than one episode every 2 h over a 12 h period .
Response to intravenous amiodarone : resolution of episodes of sustained ventricular tachycardia during the lime of the infusion and absence of other episodes for 48 h after its discontinuation.
Late response to amiodaone : resolution of episodes of sustained ventricular tachycardia after discontinuation of the infusion and during treatment with oral amiodarone .
Time to response : time of the last episode of sustained ventricular tachycardia as measured from the start of therapy with intravenous amiodarone . This time was taken to be 0 h in patients who had no episodes of sustained ventricular tachycardia after an initial bolus injection.
Major side effects: those that required either therapeutic intervention or discontinuation of the infusion .
Analysis of data. Corrected QT intervals (QTc) : QT intervals were measured in patients in whom an electrocardiogram (ECG) could be obtained at the start of the infusion and after 3 days of the infusion while they were taking no other antiarrhythmic drug (this was possible in 17 patients) . The QTc interval was calculated by correction of the QT interval to heart rate (RR) using Bazett's formula : QTc = QT/V.
Long-term follow-up: long-term follow-up was provided by referring physicians or through patient visits to the arrhythmit clinic.
Statists,s: differences between responders and nonresponders with respect to pretreatment clinical characteristics, in-hospital mortality and QTc prolongation were assessed with the use of chi-square or Student's t lest. Fischer s exact test was used instead of the chi-square test if a group was predicted to contain fewer than five subjects. Patient survival and the incidence of arrhythmia recurrence or sudden death was evaluated by life table analysis (12 Treatment protocol. The treatment protocol was determined prospectively, but changes were allowed at the discretion of the attending physician . Amiodarone was administered through a central venous line in a loading dose of 5 mg/kg body weight infused over 30 min followed by a continuous infusion of I g/24 h for 72 h . The infusion was discontinued sooner than 72 h in two patients who demonstrated a proarrhythmic effect and in five patients who responded promptly to the infusion . The infusion was continued for >72 h in six patients who did not respond to intravenous amiodarone by 72 h and in three patients who did respond by 72 h but who could not take oral amiodarone at the end of 72 h. Additional bolus injections of intravenous amiodarone (100 mg) were occasionally given to patients if their arrhythmia recurred during the infusion.
All patients who responded to intravenous amiodarone and all patients who did not respond and did not experience a proarrhythmic effect of intravenous amiodarone were treated with oral amiodarone, 800 mg/day, after the end of the infusion. Other therapies were used in nonresponders when appropriate . These included other antiarrhythmic drugs, overdrive pacing, catheter ablation and endocardial resection. Patients received continuous ECG monitoring during the infusion of amiodarone (in the coronary care unit) and for at least the first 5 days after the last recurrence of ventricular tachycardia during oral amiodarone therapy. Rhythm strips were obtained of all episodes of sustained ventricular tachycardia or fibrillation and usually of episodes of unsustained arrhythmia .
Results
Patient and arrhythmia charactcrlstics. The 46 patients included had not responded to 3 .2 ± 0.4 (mean ± SD) antiarrhythmic agents . Before being treated with intravenous amiodarone, their most recent episode of ventricular tachycardia had lasted from 2 .5 h to 3 weeks (Table I) . Forty-five of the 46 patients required cardioversion at some time during their hospital course before amiodarone therapy to terminate episodes of ventricular tachycardia or fibrillation, and 20 patients required overdrive ventricular pacing . For the group as a whole, 3 .0 ± 0.4 direct current cardioversions had been required for resuscitation during the 24 h period before treatment with intravenous amiodarone . Sixteen patients had incessant ventricular tachycardia or Ventricularfibrillation in the 24 h before the start of the infusion. Ten patients had been unsuccessfully treated with intravenous bretylium tosylate before the start of the infusion .
Incidence and time course of response . Twenty-seven (58.5%) of the 46 patients responded to intravenous amiodarone, and an additional 6 patients (13%) showed a late response to amiodarone ( 84 h (Fig. 2) . The patients who eventually responded to oral There were 16 patients with incessant ventricular tachyamiodarone experienced their last episode of sustained vencardia during the 24 h before the start of infusion. The tricolor tachycardia on the 5th to 12th day after the start of incidence and time course of response in these patients were the infusion. to intravenous amiodarone and 3 (19%) ultimately responded to oral amiodarone (late response) ; 5 (31%) responded immediately (0 to 2 h) and IS of 16 responded within 72 h ; the 16th patient responding within 84 h . Of the 10 patients who had not responded to intravenous bretylium, 6 responded to intravenous amiodarone, 2 were late responders to amiodarone and 2 were nonresponders. Predictors of in-hospital response . Of the pretreatment clinical characteristics evaluated to predict a response to intravenous amiodarone or to the combination of intravenous plus oral amiodarone, only an ejection fraction >25% predicted a positive response (Table 2) .
Hospital coarse and regimen at discharge. In the 33 responders, other antiarrhythmic drugs that had previously failed to control the arrhythmia were used during the infusion in 15 patients. Six of these 15 patients were eveatually discharged on another antiarrhythmic agent in addition to amiodarone. Other antiarrhythmic drugs were used at some time during the infusion in all nonresponders .
Responders and nonresponders showed marked differences in overall hospital mortality (4 of 33 versus 9 of 13, respectively, p < 0 .001) and in deaths due to arrhythmia (arrhythmic mortality) (2 of 33 versus 7 of 13, respectively, p < 0 .001) . Arrhythmic deaths in nonresponders occurred on days 4 to 8 in five patients and on days 10 and 15 in the other two patients . Nonpharmacologic therapy was used whenever appropriate in nonresponders . Of the seven patients in whom non . pharmacologic therapy could be used (surgery five, catheter ablation one, overdrive ventricular pacing one, three (43%) died, whereas all six patients for whom such therapy could not be used died (p < 0.05).
Of the 27 responders to intravenous amiodarone, 6 had recurrent ventricular tachycardia on days 6 to 8. Of these, two died of recurrent ventricular tachycardia, one required the addition of another antiarrhythmic agent to oral amiodarone before discharge and three were eventually discharged receiving oral amiodarone as the only antiarrhythmic agent .
Major side effects . Side effects requiring other interventions or discontinuation of the infusion occurred in six patients (13%). Hypotension requiring active treatment oc. curred in two patients . One patient, who had an ejection fraction of 42%, developed hypotension I h after receiving a loading dose of intravenous amiodarone along with infusions of bretylium and lidocaine hydrochloride ; dopamine was required for I h . The other patient developed hypotension 3 h after the start of the infusion. This patient had an ejection fraction of 20% and had significant congestive heart failure before the infusion . Treatment with dopamine was started and blood pressure normalized immediately ; he was treated with dopamine and nitroprusside for 2 days . Intravenous amiodarone was continued for a total of 3 days without other episodes of hypotension. Of the other 46 patients, 6 were being treated with pressor agents at the start of the infusion and continued to receive these agents during part or all of the time of the infusion . Therefore, hypotension caused by intravenous amiodarone could not be assessed in these patients. All six of these patients had a past history of congestive heart failure and three had an ejection fraction <25%. However, 13 other patients with a history of congestive heart failure and 13 patients with an ejection fraction <25% who were included in this study did not experience hypotension during the infusion .
Two patients required pacing for sinus bradycardia. In JACC Vol . 12. No. 4 October 1580 :10) 5 -22 CAI) =coronary artery disease : EF = ejection ratchet : MI = myocardial infarction : NS -our significant: VT = ventricular tachycardia: other abbreviations as in Table l . one patient, symptomatic bradycardia occurred I h after the infusion was started and temporary pacing was required for 8 h. The other patient had been treated with intravenous amiodarone for 48 h and oral amiodarone for 3 days when he developed symptomatic sinus bradycardia with an escape functional rhythm at 40 beatsimin . This was the only patient who required permanent pacing as a result of amiodarone therapy.
Two patients with episodes of recurrent mouoeoorphic ventricular tachycardia developed polyotorpltous ventricular tachycardia after intravenous arniodaroere . The QTc interval for these patients lengthened from 400 and 390 ms before administration of amiodarone to 510 and 650 ms, respectively, after 2 days of intravenous and I day of oral amiodarone . Oral amiodarone was continued in one of the patients for an additional 5 days when it had to be discontinued because of development of polymorphous ventricular tachycardia. The patient was managed with phenytoin and overdrive ventricular pacing and was eventually discharged on this regimen . Amiodarone was discontinued immediately in the second patient but this patient died of refractory polymorphous ventricular tachycardia and fibrillation on the 4th day of therapy .
Corrected QT interval (Table 3) . After 3 days of amiodarune treatment the QTc interval was prolonged by 720 ms in 12 of the 17 patients studied . There was no difference in either absolute or percent QTc prolongation between responders and nonresponders, excluding the two patients who experienced arrhythmia exacerbation . The latter two patients had the greatest QTc prolongation, 120 and 260 ms, respectively, compared with a maximum of 100 ms for the other 15 patients . Similar results were found in evaluation of the uncorrected QT intervals .
Long-term follow-up . Of the 29 responders who were discharged from the hospital, follow-up was available for 27 . For these 27 patients, the cumulative mortality at I year of follow-up was 23 ± 8% (mean'_ SEM by life table analysis) and at 2 years was 46'_ 11%. The cumulative mortality due to arrhythmia recurrence or sudden death at I year was 13 ± 4% and at 2 years was 23 2 7% . The overall arrhythmia recurrence rate at 2 years was 25 ± 9%. Of the 12 deaths that occurred during follow-up, 6 were arrhythmic or sudden . 4 Table 3 were due to congestive heart failure and 2 were of noncardiac cause .
Of the four nonresponders who were discharged from the hospital, follow-up was available for all four. One of these patients (25%) died suddenly at 1 .3 years of follow-up.
Discussion
In contrast to oral amiodarone, which requires 8 days to 4 weeks to be fully effective in patients with ventricular arrhythmias (2-4), intravenously administered amiodarone was shown in our study to be rapidly effective (0 to 84 h) in 58 .5% of patients with drug-refractory recurrent ventricular tachycardia and ventricular fibrillation . It was effective in combination with oral amiodarone in an additional 13% of patients in 5 to 12 days . The reason for the delay in the onset of effect in the second group of patients is not apparent from our study . The rapid onset of the antiarrhythmic effect of intravenous amiodarone is even more impressive when one considers that in 33% of patients, the effect is virtually immediate (0 to 2 h) .
Possible reasons for rapid onset of action, A rapid onset of antiarrhythmic effect of intravenous amiodarone has not been fully accepted because of conflicting reports of the agent's effect on the ventricular effective refractory period. Hariman et al . (13) and Wellens et al . (14) reported a lack of effect of intravenous amiodarone on the ventricular effective refractory period after a dose of5 mg/kg, whereas Morady et al . (15) reported a moderate effect after a dose of 10 mg/kg. An effect on ventricular effective refractory period, however, may not be a requirement for an antiarrhythmic effect of amiodarone for at least two reasons . First, amiodarone may act predominantly on diseased myocardium, as suggested by Hariman et al. (13), and may therefore not affect the measured ventricular effective refractory period at electrophysiologic study. Second, amiodarone may exert antiarrhythmic effects (such as slowing of conduction) independent of changes in refractoriness . Support for the latter hypothesis was provided by Mason et al . (16) , who demonstrated that amiodarone primarily affects the sodium channel in the inactivated state, an effect that would lead to slowing of conduction without affecting refractoriness .
Because the primary mode of antiarrhythmic effect of amiodarone is uncertain, the reason for the more rapid onset of effect of intravenous amiodarone compared with that of oral amiodarone is not clear. One possible explanation is a more rapid attainment of a therapeutic serum level with intravenous as compared with oral amiodarone . Mostow et al. (17) suggested that serum concentrations of amiodarone associated with therapeutic responses in patients with recurrent ventricular tachycardia are >1 .5 pg/ml. Haffajee et al. (I8) reported recurrence of ventricular tachycardia and fibtilation when serum levels of amiodarone decreased to <l .u ,g/ml . Successful treatment with oral amiodarone has JACC Vo1. 12, No. 4 October 1988 4 October :1015 been reported (19) at serum concentrations as low as 0 .1 pg/ ml, however. Concentrations of 1 .0 to 1 .5 pg/ml are achieved and maintained with oral amiodarone only after several days of treatment, whereas they are achieved and exceeded immediately after a 5 mg/kg infusion over 30 min (20) (21) (22) . The concentration is maintained at > 1 pg/mI when such a bolus injection is followed by a continuous infusion of 10 to 20 mg/kg per day (23) .
Predictors of positive response . In addition to finding that intravenous amiodarone is rapidly effective, we observed that the only pretreatment clinical characteristic that predicted a higher response rate to amiodarone was an ejection fraction >25% . A higher efficacy of antiarrhythmic drugs in patients with better left ventricular function has been reported with other antarrhythmic agents (24) (25) (26) .
Because all the patients in this study who had received bretylium before treatment with intravenous amiodarone had failed to respond to it, we could not assess whether response to bretylium can predict response to intravenous amiodarone . However, we found that in the 10 patients who had been unsuccessfully treated with bretylium therapy, 8 ultimately responded to amiodarone, suggesting a difference in the antiarrhythmic effect of these two drugs, both currently classified as class III .
QTc analysis. The efficacy oflong-term therapy with oral amiodarone has been related to QT and QTc prolongation (27) . We found, however, that responders and nonresponders to intravenous amiodarone did not differ in the magnitude or percent of QT or QTc prolongation . Whether this difference between our findings and those reported for oral amiodarone indicates a difference in the mechanism of action of oral versus intravenous amiodarone remains to be determined. We also found that the two patients who developed a proarrhythmic response to intravenous amiodarone had more marked QT and QTc prolongation when compared with the group as a whole. This finding requires validation in a larger group of patients.
Long-term follow-up. Long-term follow-up shows that the incidence of recurrent ventricular arrhythmia (25%) . the cumulative mortality due to arrhythmia recurrence or sudden death (23%) and the cumulative overall mortality (46%) at 2 years for responders discharged from the hospital on oral amiodarone are high . These findings suggest that in the future, patients who require intravenous amiodarone for drug-refractory ventricular tachycardia or ventricular fibrillation should be considered for other treatment modalities at the time of hospital discharge . These can include automatic implantable cardioyerter-defibrillator placement, coronary artery bypass grafting and cardiac transplantation in appropriate patients . The clinical role of invasive electrophysiologic testing in the long-term management of patients followed up on oral amiodarone therapy is still controversial (28) (29) (30) .
Limitations of she study . The causes for initiation of ventricular arrhythmias are frequently unclear . It may, A second limitation of our study is the unc'rtainty involved in attributing a successful response t3 the ant : . arrhythmic effect of amiodarone because additional antiarrhythmic drugs were used in 15 of 33 responders . That the positive response was primarily due to amiodarone is suggested by the finding that all the drugs used concurrently with amiodarone had been used without success before the start of the infusion, and that the great majority of responders were discharged on amiodarone alone .
Fb:ally, no amiodarone serum levels were measured in this study . Serum levels with infusion protocols similar to ours have been reported by others (19) (20) (21) (22) . However, the comparison of serum levels in responders and nonresponders may help in the design of a more effective infusion protoualin the future .
Cltnktd implications, We found a remarkable efficacy of intravenous amiodarone in critically ill patients with recurrent ventricular arrhythmias. We found that those destined to respond did so for the most part early in the treatment course (i .e ., within 3 days). Those who do not respond early might best be evaluated for alternative (including nonpharmacologic) therapy. The only clinical characteristic associated with a response to intravenous amiodarone was better left ventricular function . A negative response to bretylium did not predict a similar response to intravenous amiodarone.
The long-term prognosis of responders who were discharged from the hospital on oral amiodarone therapy was found to be poor ; therefore, alternative modes of therapy should be considered once the patient's condition is stabilized.
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